An open-label study of aripiprazole for methamphetamine induced psychosis

Objective: This study aimed to explore the therapeutic effects and tolerability of aripiprazole in the treatment of psychosis among methamphetamine dependent patients. Methods: This was an open label single arm prospective study conducted at the University Malaya Medical Centre (UMMC). The study sub...

Full description

Saved in:
Bibliographic Details
Main Authors: Sulaiman, A.H., Gill, J.S., Said, M.A., Habil, M.H., Zainal, N.Z., Guan, N.C.
Format: Article
Language:English
Published: 2012
Subjects:
Online Access:http://eprints.um.edu.my/10976/1/An_open-label_study_of_aripiprazole.pdf
http://eprints.um.edu.my/10976/
http://www.scopemed.org/?mno=13311
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.10976
record_format eprints
spelling my.um.eprints.109762014-08-05T02:49:33Z http://eprints.um.edu.my/10976/ An open-label study of aripiprazole for methamphetamine induced psychosis Sulaiman, A.H. Gill, J.S. Said, M.A. Habil, M.H. Zainal, N.Z. Guan, N.C. BF Psychology R Medicine Objective: This study aimed to explore the therapeutic effects and tolerability of aripiprazole in the treatment of psychosis among methamphetamine dependent patients. Methods: This was an open label single arm prospective study conducted at the University Malaya Medical Centre (UMMC). The study subjects included treatment naive patients with a current diagnosis of methamphetamine dependence with co-occurring acute psychotic symptoms based on the Diagnostic and Statistical Manual of Mental Disorders-IV (DSMIV). Eligible patients were treated with an initial dose of 5-10 mg aripiprazole followed by flexible doses (5-15mg/day) from day 2 to 14. Results: Out of 49 patients enrolled, 41 patients (83.7) completed the study. At baseline the mean PANSS total score was 79.2 +/- 13.7 and the mean CGI-S score was 4.3 +/- 0.5. There was a statistically significant decline in the mean PANSS-total and CGI-S scores over the course of the study. The mean reduction was 27.6 +/- 21.4 point (p < 0.05, 95 Cl (-34.8, -20.4)) from baseline on day 14 for total PANSS score and 2.0 +/- 1.2 point (p < 0.05, 95 Cl (-2.4, -1.6) for CGI-S. Aripiprazole was generally well tolerated during the study. Adverse events were reported in 10 (20.4) patients. No statistically significant changes were noted with respect to movement-related adverse events. Conclusions: This study found that aripiprazole improved the psychotic symptoms associated with methamphetamine use. It was generally well tolerated with mild to moderate adverse events. Based on these results aripiprazole might be an effective and safe option for the treatment of methamphetamine induced psychosis. 2012 Article PeerReviewed application/pdf en http://eprints.um.edu.my/10976/1/An_open-label_study_of_aripiprazole.pdf Sulaiman, A.H. and Gill, J.S. and Said, M.A. and Habil, M.H. and Zainal, N.Z. and Guan, N.C. (2012) An open-label study of aripiprazole for methamphetamine induced psychosis. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology, 22 (2). pp. 121-129. ISSN 1017-7833 http://www.scopemed.org/?mno=13311 10.5455/bcp.20120412020813
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
language English
topic BF Psychology
R Medicine
spellingShingle BF Psychology
R Medicine
Sulaiman, A.H.
Gill, J.S.
Said, M.A.
Habil, M.H.
Zainal, N.Z.
Guan, N.C.
An open-label study of aripiprazole for methamphetamine induced psychosis
description Objective: This study aimed to explore the therapeutic effects and tolerability of aripiprazole in the treatment of psychosis among methamphetamine dependent patients. Methods: This was an open label single arm prospective study conducted at the University Malaya Medical Centre (UMMC). The study subjects included treatment naive patients with a current diagnosis of methamphetamine dependence with co-occurring acute psychotic symptoms based on the Diagnostic and Statistical Manual of Mental Disorders-IV (DSMIV). Eligible patients were treated with an initial dose of 5-10 mg aripiprazole followed by flexible doses (5-15mg/day) from day 2 to 14. Results: Out of 49 patients enrolled, 41 patients (83.7) completed the study. At baseline the mean PANSS total score was 79.2 +/- 13.7 and the mean CGI-S score was 4.3 +/- 0.5. There was a statistically significant decline in the mean PANSS-total and CGI-S scores over the course of the study. The mean reduction was 27.6 +/- 21.4 point (p < 0.05, 95 Cl (-34.8, -20.4)) from baseline on day 14 for total PANSS score and 2.0 +/- 1.2 point (p < 0.05, 95 Cl (-2.4, -1.6) for CGI-S. Aripiprazole was generally well tolerated during the study. Adverse events were reported in 10 (20.4) patients. No statistically significant changes were noted with respect to movement-related adverse events. Conclusions: This study found that aripiprazole improved the psychotic symptoms associated with methamphetamine use. It was generally well tolerated with mild to moderate adverse events. Based on these results aripiprazole might be an effective and safe option for the treatment of methamphetamine induced psychosis.
format Article
author Sulaiman, A.H.
Gill, J.S.
Said, M.A.
Habil, M.H.
Zainal, N.Z.
Guan, N.C.
author_facet Sulaiman, A.H.
Gill, J.S.
Said, M.A.
Habil, M.H.
Zainal, N.Z.
Guan, N.C.
author_sort Sulaiman, A.H.
title An open-label study of aripiprazole for methamphetamine induced psychosis
title_short An open-label study of aripiprazole for methamphetamine induced psychosis
title_full An open-label study of aripiprazole for methamphetamine induced psychosis
title_fullStr An open-label study of aripiprazole for methamphetamine induced psychosis
title_full_unstemmed An open-label study of aripiprazole for methamphetamine induced psychosis
title_sort open-label study of aripiprazole for methamphetamine induced psychosis
publishDate 2012
url http://eprints.um.edu.my/10976/1/An_open-label_study_of_aripiprazole.pdf
http://eprints.um.edu.my/10976/
http://www.scopemed.org/?mno=13311
_version_ 1643688934047219712
score 13.222552